|
Ginkgo biloba is one of the most popular medicinal plants in Australia.
According to the Australian Government, there are about 400 Ginkgo biloba merchandises on the Australian market.
Despite the obvious popularity of Ginkgo biloba, those who use it often have little idea of its history and the wide scope of its applications. Here are a few things you may not have known.
Paleobotanists say that the Ginkgo biloba tree was around for about 270 million years. This is why scientists refer to it as a living fossil. It appeared during the Permian period, which means that it was already tens of millions of years old when the first dinosaurs appeared during the Triassic period, which began 245 million years ago. The appearance of vegetable eating dinosaurs was the best thing that ever happened to the Ginkgo biloba tree. The dinosaurs dined on the fleshy covering of the seeds, then spread the seeds far and wide in their droppings. We know this because scientists have discovered Ginkgo biloba seeds in fossilised dinosaur poo. During this time Ginkgo biloba thrived in areas which are acknowledged today as Asia, Europe and North America. After the dinosaurs were wiped out 65 million years ago Ginkgo biloba's range shrank until today it grows wild only in certain parts of China. The survival of the tree to the modern era was attributed to Buddhist monks, who cultivated it as an ornamental vegetable in monastery gardens. The Ginkgo biloba tree that we have today has not changed substantially for the past 170 million years.
The medicinal use of Ginkgo biloba has a long history. The leaves and seeds have both been used in traditional Chinese medicine. The earliest acknowledged mention of the medicinal use of the leaves was during the Han dynasty between 206 Bc and 220 Ad. Chinese medicine condensed on the seeds. The next significant mention in literature of the use of the leaves was in 1436, during the Ming dynasty. The literature mentioned the use of the leaves as a treatment for head sores and freckles.
According to the authoritative American Herbal Pharmacopeia, the first Western pharmaceutical company to produce a medicine from the leaves of the Ginkgo biloba tree was the German company Dr Willmar Schwabe Pharmaceuticals which, in 1965, launched Tebonin®. Since that time numerous published clinical tests have been conducted on Ginkgo biloba leafage concentrate for a range of medical conditions. More compared with 400 clinical and pharmacological trials have been done on the concentrate Egb 761® used in Tebonin®.
Egb 761® was established in published analyses to be what folk refer to as a smart pill. It was established to improve cognitive tune up, combined with memory and a general sense of well being. A paper published in the medical journal Pharmacology and Therapeutics 1/2007, 3 9 reported that the task tune up of white collar workers who were given 240 mg a day of Tebonin® improved crucially when their work related error rate was reduced by 30 per cent.
Tebonin® was established to improve blood circulation during the entire the body by allowing the blood to flow more freely, so it may be of use for the relief of conditions that involve circulatory problems. These include tinnitus, vertigo and cold hands and feet. Analyses on the use of Ginkgo biloba concentrate for the relief of such conditions have been published in medical journals.
Tebonin® is made with the scientifically proven Ginkgo biloba leafage concentrate Egb 761®. A 2001 study published in the Journal of the American Medical Association showed that Egb 761® was in a class of its own among Gingko biloba merchandises. Professor Meinhard Kieser, co author of the study, wrote: Previous research comparing Egb 761® against other infusions showed that only Egb 761® elevated activity in all areas of the brain.
Egb 761® is the result of a patented process of extraction and standardisation. During the merchandiseion process, the chemical compounds that contribute to the merchandise's efficacy are fortified by a factor of up to 100, while any components that do not contribute to the efficacy are eliminated resulting in a high quality merchandise. A tonne of the raw Gingko biloba leaves yields only 20kg of Egb 761®.
Egb 761® is licenced by national drug regulators in more compared with 80 countries, including major markets in Europe like France, Switzerland, Germany and Sweden.
Egb 761® complies with or exceeds all relevant national and international pharmaceutical quality protocols and monographs relating to Ginkgo biloba, American Herbal Pharmacopoeia Ahp. Egb 761 consists of 24 per cent flavone glycosides, United States Pharmacopoeia Usp, like the German Commission E, European Pharmacopoeia Ep, World Health Organisation Who, German Pharmacopoeia Dab, six per cent terpene lactones and fewer compared with 5ppm ginkgolic acids.
|
